Skip to main content

According to results recently published in The New England Journal of Medicine, neoadjuvant chemotherapy appears to improve survival in patients undergoing a cystectomy for bladder cancer.

The bladder is a hollow organ in the lower abdomen. Its primary function is to store urine, the waste that is produced when the kidneys filter the blood. Transitional cell carcinoma refers to bladder cancer involving the cells that line the inside of the bladder. Treatment of locally advanced bladder cancer (cancer that has invaded the bladder wall into the muscle, but cannot be detected elsewhere in the body) usually consists of the surgical removal of the bladder (cystectomy) and/or chemotherapy following surgery. However, approximately 50% to 60% of these patients ultimately experience a cancer recurrence, most of which are in the form of distant metastases (cancer spread from its site of origin to distant sites in the body). Thus, researchers are evaluating novel therapeutic approaches in order to reduce recurrences and ultimately improve survival for patients with locally advanced bladder cancer.

Bladder Cancer CancerConnect

Researchers have increasingly been evaluating neoadjuvant therapy in bladder cancer because pre-operative treatment can shrink some bladder cancers, and therefore may allow more complete surgical removal of the cancer. In addition because systemic therapy with  chemotherapy or immunotherapy kills undetectable cancer cells in the body, it may help prevent the spread of cancer when used initially rather than waiting for patient recovery following the surgical procedure.

Researchers affiliated with the Southwest Oncology Group recently conducted a clinical trial to further evaluate neoadjuvant chemotherapy in patients with locally advanced bladder cancer. This trial involved over 300 patients who were treated either with neoadjuvant chemotherapy consisting of methotrexate, vinblastine, doxorubicin and Platinol® (MVAC) followed by a cystectomy or a cystectomy alone, and outcomes from the two groups were directly compared. 

The average duration of survival for patients less than 65 years of age was 104 months for those treated with neoadjuvant therapy, compared with 67 months for those treated with cystectomy only. For patients 65 years or older, the average survival was 61 months for those treated with neoadjuvant therapy, compared to only 30 months for those treated with cystectomy only. At approximately 5 years following therapy, 57% of patients treated with neoadjuvant therapy were alive, compared with only 43% of patients treated with cystectomy only. Treatment with neoadjuvant therapy caused moderate side effects, particularly low white blood cell levels. However, there were no treatment-related deaths and no complications from surgery due to treatment with chemotherapy.

Scroll to Continue

Recommended Articles

Image placeholder title

Kisqali Improves Survival in Premenopausal ER+ Advanced Breast Cancer

Kisqali prolongs survival for Pre-menopausal ER positive HER2 Neg breast cancer. San Antonio 2020 update.


GARNET Study Leads to FDA Approval for Jemperli for Uterine/Endometrial Cancer

Jemperli immunotherapy advances treatment of endometrial cancer, especially those with MSI-H or dMMR defects.

The researchers concluded that neoadjuvant chemotherapy with MVAC improves survival in patients with locally advanced bladder cancer who are to undergo a cystectomy. Patients with locally advanced bladder cancer should discuss the risks and benefits of neoadjuvant chemotherapy with MVAC, Gemzar®/Platinol® or other chemotherapy regimens with their physician.2

Dr. Wesley Yip, MD, of Memorial Sloan Kettering Cancer Center in New York, New York presented the most recent study results on neoadjuvant therapy for bladder cancer at the ASCO Genitourinary Cancers Symposium 2022.

Genitourinary Cancer Newsletter 490 GU

The multicenter, phase 2 study included 57 evaluable patients with high-grade bladder cancer treated with 4 cycles of gemcitabine plus cisplatin chemotherapy, followed by radical nephroureterectomy or uterectomy with templated lymph node dissection. All patients underwent surgery at a median of 7 weeks. A pathologic response rate rate of was 63% was reported which included a complete response in 19% of patients. With median follow-up was 3.1 years. The progression-free survival rate was 78% at 2 years and 65% at 5 years. The overall survival rate was 93% at 2 years and 79% at 5 years.3


  1. Grossman H, Natale R, Tangen C, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. The New England Journal of Medicine. 2003;349:859-866.
  2. Bamias A, Deliveliotis C, Karayiannis A, et al. Neoadjuvant chemotherapy with docetaxel and cisplatin in patients with high-risk resectable bladder carcinoma: long-term results. European Urology. 2004; 46: 344-351.
  3. Yip W, Coleman J, Wong NC, et al. Final results of a multicenter prospective phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy in patients with high-grade upper tract urothelial carcinoma. Presented at ASCO GU 2022; February 17-19, 2022. Abstract 440.